Latozinemab
4 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.
Trials
4
Ongoing
0
Recruiting
0
Completed
3
Sites
60
Countries
16
Endpoints
43
Composite endpoints
0
Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 43 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.
Development
Where the program stands
Trials by phase
Trials by status
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Most-measured metrics
Top 20 metrics across this asset's endpoints
Normalized metric codes are available for 2 of 43 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.
1
1
Trials
Trials for this asset
Every trial for this asset, with the same search, filters, and sort as the Trials tab.
4 of 4
| Asset / Disease area | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| NCT04374136A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3) | Latozinemab Frontotemporal dementia | At-risk or symptomatic FTD · GRN mutation required | Ph 3 | Terminated | 44 | Sep 2025 | - | |
| NCT03987295A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2) | Latozinemab Frontotemporal dementia | GRN/C9orf72 mutation required | Ph 2 | Completed | 12 | Jun 2024 | - | results |
| NCT03636204A First in Human Study in Healthy Volunteers and in Participants With Frontotemporal Dementia With Granulin (GRN) Mutation | Latozinemab Frontotemporal dementia | Age 18-80 | Ph 1 | Completed | 8 | Dec 2019 | 1 | |
| "MAD"Multiple Ascending Dose Safety, Tolerability, PK Study of AL001 in Alzheimer's Disease Patients & Healthy Adult Subjects | Latozinemab Alzheimer’s disease | mild-to-moderate AD | Ph 1/2 | Completed | 2 | Apr 2023 | - | results |
Showing 1-4 of 4 trials